The Paris Private Equity team advised Stago, a global leader in diagnostics and a specialist in hemostasis, on its exclusive negotiations with a consortium led by ARCHIMED, an investment fund dedicated to the healthcare sector, with a view to acquiring a majority stake in the group. La Caisse (formerly Caisse de dépôt et Placement du Québec) would invest alongside ARCHIMED as a minority investor.
This transaction would provide Stago with the resources needed to accelerate its growth strategy, reinforce its technological and scientific leadership, and advance its long-term strategic vision, supported by the recognized expertise of its teams.
The transaction is expected to be finalized in the second quarter of 2026. It remains subject to the information and consultation procedure with the relevant employee representative bodies within the Stago group, as well as prior regulatory approvals.
Founded after World War II, Stago had become a leading player specialized in Hemostasis. With nearly 2,600 employees worldwide, Stago develops and markets automated systems for blood analysis in coagulation.
The Goodwin team included:
- In Paris, Maxence Bloch, William Robert, Pauline Louis, Sibel Tekesultan and Julien Quaranta on corporate matters, Adrien Paturaud and Benjamin Filiatre on financing matters, and Charles-Henri de Gouvion Saint Cyr and Gauthier Pinabiaux on tax matters.
- In London, Eram Khan on antitrust regulatory aspects.
- In the US, Simone Waterbury and Arom Yun on antitrust regulatory aspects.